507486057 09/12/2022

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT7532947

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
DAVID T. JOHNSON	09/06/2022
EVAN ECKERSLEY	09/06/2022
PHILIP MILLER	09/08/2022
BENJAMIN SCIRE	09/06/2022
NICHOLAS YANTISS	09/07/2022

RECEIVING PARTY DATA

Name:	ICARUS MEDICAL, LLC	
Street Address:	609 WEST MARKET STREET, SUITE 114	
City:	CHARLOTTESVILLE	
State/Country:	VIRGINIA	
Postal Code:	22902	

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17902683

CORRESPONDENCE DATA

Fax Number:

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: nevans@woodsrogers.com

Correspondent Name: NATHAN A. EVANS

Address Line 1:123 EAST MAIN STREET, 5TH FLOORAddress Line 4:CHARLOTTESVILLE, VIRGINIA 22902

NAME OF SUBMITTER:	NATHAN A. EVANS
SIGNATURE:	/Nathan A. Evans/
DATE SIGNED:	09/12/2022

Total Attachments: 3

source=KAFO-US Patent Assignment-2#page1.tif source=KAFO-US Patent Assignment-2#page2.tif source=KAFO-US Patent Assignment-2#page3.tif

PATENT 507486057 REEL: 061062 FRAME: 0881

WORLDWIDE ASSIGNMENT

WHEREAS, we, the below named inventors, (hereinafter Assignors), have made the inventions described in the following U.S. patent application:

Unloading Knee-Ankle-Foot Orthotic Apparatus with Conforming and Distracting Hinge

(and variations of that title)

for which the following U.S. Nonprovisional Pate	ent Application No. was filed:
U.S. Appl. No. 17/902,683, filed September 2, 20)22, and
and for which U.S. Patent Application No	, was filed,
and for which PCT Application No.	, was filed
(I hereby authorize the application numbers and f	iling dates to be inserted when known)

WHEREAS, ICARUS MEDICAL, LLC, having an office at 609 West Market Street, Suite 114, Charlottesville, VA 22902 USA (hereinafter Assignee), is desirous of securing the entire right, title, and interest in and to these inventions in all countries throughout the world, and in and to the above-identified patent applications and all national patent applications based on the patent applications or claiming benefit of or to the patent applications throughout the world, and any Letters Patent issued or to be issued upon all applications based on the applications or claiming benefit of or to the applications throughout the world;

NOW THEREFORE, effective as of the earliest priority date claimed for the patent applications, be it known that for good and valuable consideration, the receipt of which from Assignee is hereby acknowledged, we as Assignors, have sold, assigned, transferred, and set over, and do hereby sell, assign, transfer, and set over unto Assignee, its lawful successors and assigns, the entire worldwide right, title, and interest in and to the above-referenced inventions and the above-referenced applications, and all divisions, renewals, continuations, and continuations-in-part thereof, and all United States Letters patent that may be granted thereon and all reissues, reexaminations, substitutions, and extensions thereto, and all Letters Patents of all countries throughout the world that might be granted thereon, and we hereby authorize and request all officials of all foreign countries whose duty it is to issue patents on applications as described above, to issue all Letters Patents for these inventions to Assignee, its successors and assigns, in accordance with the terms of this Assignment; our sale, assignment, transfer, and setting over further includes any right to sue for past infringement and to sue for all other legal or equitable rights related to the inventions and in said applications;

AND, we agree that, prior to filing said applications referenced herein, said Assignee was specifically entitled to apply for and claim priority of said applications referenced herein and is

PATENT REEL: 061062 FRAME: 0882

(Worldwide Rights)
U.S. and PCT Patent Applications
Page 2 of 3

entitled to apply for and claim priority to any PCT applications or foreign equivalents that claim priority to said applications referenced herein;

AND, we agree and acknowledge that: (i) Assignee is the real party in interest for said applications and has a sufficient proprietary interest under 35 U.S.C. §§ 115 and 118 in said applications to make applications for patent on behalf of and as an agent for us, (ii) Assignee has the right, but is not required, to file a Substitute Statement under 35 U.S.C. § 115, and (iii) said Assignee may make such patent applications as necessary and determined solely by the Assignee to preserve the rights of the parties;

AND, we covenant that we have the full right to convey the interest assigned by this Assignment, and we have not executed and will not execute any agreement in conflict with this Assignment;

AND, we agree and acknowledge that we are original, first and joint inventors of the subject matter which is claimed and/or described in said applications and agree that said applications were made by us or the Assignee;

AND, we covenant with said Assignee that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by us and that full right to convey the same as herein expressed is possessed by us;

AND, we further covenant and agree that we will, without further consideration, communicate with Assignee, its successors and assigns, any facts known to us respecting these inventions, and testify in any legal proceeding, sign all lawful papers when called upon to do so, execute and deliver any and all papers that might be necessary or desirable to perfect the title to these inventions in Assignee, its successors and assigns, execute all divisional, continuation, and reissue applications, make all rightful oaths, and generally do everything possible to aid Assignee, its successors and assigns, to obtain and enforce proper patent protection for these inventions in all countries, it being understood that any expense incident to the execution of such papers shall be borne by Assignee, its successors, and assigns.

[CONTINUED ON NEXT PAGE]

PATENT REEL: 061062 FRAME: 0883

IN TESTIMONY WHEREOF, we have hereunto set our hands:

Date 0 9/06/2022	David T. Johnson David T. Johnson
Dat <u>0</u> 9/06/2022	Evan Eckersley
Dat@9/08/2022	Philip Miller Philip Miller (Sep 8, 2022 08:55 EDT) Philip Miller
Dat 9.9/06/2022	Benjamin Scire Benjamin Scire (Sep 6, 2022 09:43 EDT) Benjamin Scire
Dat 0 9/ <u>07/2022</u>	Nicholas Yantiss Nicholas Yantiss (Sep 7, 2022 10:12 EDT) Nicholas Yantiss
For ICARUS MEDICAL, LLC	
Dat Q 9/06/2022	David T. Johnson David T. Johnson Chief Executive Officer

PATENT REEL: 061062 FRAME: 0884

RECORDED: 09/12/2022